ADVERTISEMENT
Dr Choueiri Highlights Nivolumab Plus Cabozantinib vs Sunitinib for Advanced RCC
02/16/2021
Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, shares results from a new analysis of the phase 3 Checkmate 9ER trial of cabozantinib combined with nivolumab for the first-line treatment of advanced renal cell carcinoma (RCC). These data were presented at the 2021 Virtual ASCO Genitourinary Cancers Symposium.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement